该股主要指标及行业内排名如下： 尚荣医疗2025年三季报显示，前三季度公司主营收入7.54亿元，同比下降24.85%；归母净利润-3512.53 万元，同比下降338.5%；扣非净利润-4232.55万元，同比下降1336.59%；其中2025年第三季度，公司单 季度主营收入2.25亿元，同比下降39.25%；单季度归母净利润-2736.7万元，同比下降4004.28%；单季度 扣非净利润-2980.68万元，同比下降2776.04%；负债率23.31%，投资收益1020.49万元，财务费 用-378.91万元，毛利率14.35%。尚荣医疗（002551）主营业务：医疗产品生产销售、医疗服务、健康 产业运营等。 证券之星消息，截至2025年12月26日收盘，尚荣医疗(002551)报收于3.7元，下跌1.07%，换手率 1.34%，成交量8.19万手，成交额3044.82万元。 12月26日的资金流向数据方面，主力资金净流入262.97万元，占总成交额8.64%，游资资金净流出89.41 万元，占总成交额2.94%，散户资金净流出173.56万元，占总成交额5.7%。 近5日资金流向一览见下表： 资金流向名词 ...

近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 证券之星消息，截至2025年12月25日收盘，尚荣医疗(002551)报收于3.74元，上涨1.63%，换手率 1.2%，成交量7.32万手，成交额2716.02万元。 12月25日的资金流向数据方面，主力资金净流入238.38万元，占总成交额8.78%，游资资金净流出20.73 万元，占总成交额0.76%，散户资金净流出217.66万元，占总成交额8.01%。 尚荣医疗2025年三季报显示，前三季度公司主营收入7.54亿元，同比下降24.85%；归母净利润-3512.53 万元，同比下降338.5%；扣非净利润-4232.55万元，同比下降1336.59%；其中2025年第三季度，公司单 季度主营收入2.25亿元，同比下降39.25%；单季度归母净利润-2736.7万元，同比下降4004.28%；单季度 扣非净利润-2980.68万元，同比下降2776.04%；负债率23.31%，投资收益1020.49万元，财务费 用-378.91万元，毛利率14.35%。尚荣医疗（002551）主营业务：医疗产品生产销售、医疗服务、健康 产业运营等。 资金流向名 ...

证券之星消息，截至2025年12月24日收盘，尚荣医疗(002551)报收于3.68元，上涨0.0%，换手率 1.09%，成交量6.68万手，成交额2464.49万元。 12月24日的资金流向数据方面，主力资金净流入121.17万元，占总成交额4.92%，游资资金净流出 217.73万元，占总成交额8.83%，散户资金净流入96.56万元，占总成交额3.92%。 尚荣医疗2025年三季报显示，前三季度公司主营收入7.54亿元，同比下降24.85%；归母净利润-3512.53 万元，同比下降338.5%；扣非净利润-4232.55万元，同比下降1336.59%；其中2025年第三季度，公司单 季度主营收入2.25亿元，同比下降39.25%；单季度归母净利润-2736.7万元，同比下降4004.28%；单季度 扣非净利润-2980.68万元，同比下降2776.04%；负债率23.31%，投资收益1020.49万元，财务费 用-378.91万元，毛利率14.35%。尚荣医疗（002551）主营业务：医疗产品生产销售、医疗服务、健康 产业运营等。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性 ...

资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 该股主要指标及行业内排名如下： 尚荣医疗2025年三季报显示，前三季度公司主营收入7.54亿元，同比下降24.85%；归母净利润-3512.53 万元，同比下降338.5%；扣非净利润-4232.55万元，同比下降1336.59%；其中2025年第三季度，公司单 季度主营收入2.25亿元，同比下降39.25%；单季度归母净利润-2736.7万元，同比下降4004.28%；单季度 扣非净利润-2980.68万元，同比下降2776.04%；负债率23.31%，投资收益1020.49万元，财务费 用-378.91万元，毛利率14.35%。尚荣医疗（002551）主营业务：医疗产品生产销售、 ...

证券之星消息，截至2025年12月12日收盘，尚荣医疗(002551)报收于3.61元，下跌1.1%，换手率 1.95%，成交量11.89万手，成交额4323.6万元。 12月12日的资金流向数据方面，主力资金净流出140.42万元，占总成交额3.25%，游资资金净流出17.78 万元，占总成交额0.41%，散户资金净流入158.2万元，占总成交额3.66%。 近5日资金流向一览见下表： 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净流入 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-12 | 3.61 | -1.10% | -140.42万 | -3.25% | -17.78万 | -0.41% | 158.20万 | 3.66% | | 2025-12-11 | | 3 ...

证券之星消息，截至2025年12月8日收盘，尚荣医疗(002551)报收于3.92元，上涨0.0%，换手率1.54%， 成交量9.44万手，成交额3708.63万元。 | 指标 | 尚荣医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 33.14亿元 | 110.14亿元 | 97 124 | | 净资产 | 27.3亿元 | 39.1亿元 | 57 124 | | 净利润 | -3512.53万元 | 2.12亿元 | 111 124 | | 市盈率(动) | -70.77 | 65.06 | - 124 | | 市净率 | 1.28 | 3.85 | 15 124 | | 毛利率 | 14.35% | 51.22% | 119 124 | | 净利率 | -4.6% | 9.57% | 103 124 | | ROE | -1.34% | 0.15% | 107 124 | 尚荣医疗2025年三季报显示，前三季度公司主营收入7.54亿元，同比下降24.85%；归母净利润-3512.53 万元，同比下降338.5%；扣非净利润-4232.55万 ...

Core Insights - The stock of Shangrong Medical (002551) closed at 3.95 yuan on December 1, 2025, with an increase of 0.77% and a trading volume of 120,900 hands, resulting in a transaction amount of 47.78 million yuan [1][2]. Financial Performance - For the first three quarters of 2025, Shangrong Medical reported a main revenue of 754 million yuan, a year-on-year decrease of 24.85% [3]. - The net profit attributable to shareholders was -35.13 million yuan, a decline of 338.5% year-on-year [3]. - The third quarter alone saw a main revenue of 225 million yuan, down 39.25% year-on-year, and a net profit of -27.37 million yuan, a drop of 4004.28% year-on-year [3]. Market Position - Shangrong Medical's total market capitalization is 3.34 billion yuan, significantly lower than the industry average of 11.16 billion yuan, ranking 98 out of 124 in the medical device industry [3]. - The company has a negative price-to-earnings ratio of -71.31, compared to the industry average of 59.83, indicating poor profitability [3]. - The gross margin stands at 14.35%, which is substantially below the industry average of 51.22%, ranking 119 out of 124 [3]. Capital Flow Analysis - On December 1, 2025, the net inflow of main funds was 1.38 million yuan, accounting for 2.89% of the total transaction amount, while retail investors saw a net inflow of 1.11 million yuan, making up 2.32% [1][2]. - Over the past five days, the main funds have fluctuated, with notable net inflows and outflows, indicating varying investor sentiment [2].

Core Viewpoint - The stock of Shangrong Medical (002551) has shown a slight increase of 2.7% on November 24, 2025, closing at 3.81 yuan, despite facing significant net outflows from major and retail investors in recent days [1][2]. Financial Performance - Shangrong Medical reported a total revenue of 754 million yuan for the first three quarters of 2025, representing a year-on-year decline of 24.85% [3]. - The company recorded a net profit attributable to shareholders of -35.13 million yuan, a significant drop of 338.5% year-on-year [3]. - The third quarter of 2025 saw a single-quarter revenue of 225 million yuan, down 39.25% year-on-year, with a net profit of -27.37 million yuan, reflecting a staggering decline of 4004.28% [3]. Market Position - As of November 24, 2025, Shangrong Medical's total market capitalization stands at 3.22 billion yuan, which is significantly lower than the industry average of 10.98 billion yuan [3]. - The company's net asset value is 2.73 billion yuan, compared to the industry average of 3.89 billion yuan [3]. - Shangrong Medical's price-to-earnings ratio is -68.78, while the industry average is 55.96, indicating poor profitability [3]. Profitability Metrics - The gross margin for Shangrong Medical is 14.35%, which is substantially lower than the industry average of 51.22% [3]. - The net margin stands at -4.6%, compared to the industry average of 9.57% [3]. - Return on equity (ROE) is -1.34%, significantly below the industry average of 0.15% [3]. Recent Trading Activity - On November 24, 2025, the stock experienced a trading volume of 181,000 hands and a transaction value of 68.649 million yuan [1]. - The net outflow of major funds was 2.58 million yuan, accounting for 3.76% of the total transaction value, while retail investors saw a net inflow of 4.23 million yuan, representing 6.16% of the total [1][2].

Core Viewpoint - The financial performance of Shangrong Medical (002551) shows significant declines in revenue and profit, indicating potential challenges in the medical device industry [3]. Financial Performance - As of November 12, 2025, Shangrong Medical's stock closed at 4.08 yuan, with a slight increase of 0.25% and a trading volume of 127,400 hands, amounting to a total transaction value of 51.94 million yuan [1]. - In the third quarter of 2025, the company reported a main revenue of 225 million yuan, a year-on-year decrease of 39.25%, and a net profit attributable to shareholders of -27.37 million yuan, a decline of 4004.28% [3]. - For the first three quarters of 2025, the company's main revenue was 754 million yuan, down 24.85% year-on-year, with a net profit of -35.13 million yuan, a decrease of 338.5% [3]. Market Position - Shangrong Medical's total market capitalization is 3.45 billion yuan, significantly lower than the industry average of 11.669 billion yuan, ranking 124th in the industry [3]. - The company's net asset value stands at 2.73 billion yuan, compared to the industry average of 3.893 billion yuan, also ranking 124th [3]. - The company's gross margin is 14.35%, which is substantially below the industry average of 51.22%, ranking 119th [3]. Capital Flow - On November 12, 2025, the net inflow of main funds was 1.23 million yuan, accounting for 2.37% of the total transaction value, while retail investors experienced a net outflow of 1.19 million yuan, representing 2.28% of the total transaction value [1][2]. - Over the past five days, the main funds showed fluctuating trends, with a peak net inflow of 3.06 million yuan on November 11, 2025, and a significant net outflow of 3.57 million yuan on November 7, 2025 [2].

Core Viewpoint - The stock of Shangrong Medical (002551) has shown a slight increase of 1.5% on November 10, 2025, closing at 4.05 yuan, despite facing significant declines in revenue and profit in recent quarters [1][3]. Financial Performance - For the first three quarters of 2025, Shangrong Medical reported a main revenue of 754 million yuan, a year-on-year decrease of 24.85% [3]. - The net profit attributable to shareholders was -35.13 million yuan, representing a year-on-year decline of 338.5% [3]. - The third quarter alone saw a main revenue of 225 million yuan, down 39.25% year-on-year, with a net profit of -27.37 million yuan, a staggering decline of 4004.28% [3]. - The company’s debt ratio stands at 23.31%, with an investment income of 10.20 million yuan and financial expenses of -3.79 million yuan [3]. Market Position - Shangrong Medical's total market capitalization is 3.424 billion yuan, significantly lower than the industry average of 11.616 billion yuan, ranking 102 out of 124 in the medical device industry [3]. - The company has a negative price-to-earnings ratio of -73.12, compared to the industry average of 62.58, indicating poor profitability [3]. - The gross margin is reported at 14.35%, which is substantially below the industry average of 51.22%, ranking 119 out of 124 [3]. Capital Flow Analysis - On November 10, 2025, the net inflow of main funds was 1.90 million yuan, accounting for 3.19% of the total transaction amount, while retail investors saw a net inflow of 1.99 million yuan, making up 3.33% [1][2]. - In contrast, speculative funds experienced a net outflow of 3.89 million yuan, representing 6.52% of the total transaction amount [1][2]. - Over the past five days, the stock has seen fluctuating capital flows, with notable outflows from speculative funds on several days [2].